Remission of severe, intractable autoimmune haemolytic anaemia following matched unrelated donor transplantation

Abstract

Summary:Immune-mediated haemolytic anaemia presenting post allogeneic bone marrow transplantation is often alloimmune in origin due to ABO or minor red cell incompatibilities. Autoimmune haemolytic anaemia is also recognised, is frequently difficult to treat and overall prognosis is often poor, usually from associated problems. Here, we present a case report of autoimmune haemolysis presenting in an 8-year-old boy 6 months post allogeneic bone marrow transplant requiring 4 years of immunosuppressive therapy before remission of haemolysis. This case report highlights the fact that it is possible for haemolysis to resolve post transplant even after years of immunosuppressive therapy. Bone Marrow Transplantation (2001) 28, 791-793.

Present experience with Campath‐1H in organ transplantation and its potential use in pediatric recipients

“…The remainder of the pediatric experience in oncology and bone marrow transplantation has relied on Campath‐1G, the non‐humanized rat IgG2a isotype mentioned above, or Campath‐1M (27, 28). A considerable experience has been accumulated with Campath‐1G in children (29–42). Clearly, oncology is a different patient population with a different target population, i.e.…”

Successful treatment of severe immune hemolytic anemia after allogeneic stem cell transplantation with bortezomib: report of a case and review of literature

“…Although rituximab has been reported as effective treatment for immune hemolytic anemia in the nontransplant setting, 13 of 32 patients treated with rituximab for hemolytic anemia after allogeneic transplant did not achieve CR from RBC transfusion dependence. For patients with immune hemolytic anemia that persists after administration of steroids, IVIG, and rituximab, less immunosuppressive treatment that is more specifically targeted to plasma cells is needed, as many patients with immune hemolytic anemia die from opportunistic infections during immunosuppressive drug therapy …”

“…Severe immune hemolytic anemia alone rarely causes death in adults but is often associated with other complications and significant morbidity . Thus, early effective treatment can prevent transfusion‐related complications.…”

Stem Cell Applications for Treatment of Cancer and Autoimmune Diseases: Its Promises, Obstacles, and Future Perspectives

“…87 (Auto)immune hemolytic anemia (IHA) refers to hematologic diseases where either autoreactive antibodies or complement against membrane proteins triggers the early destruction of erythrocytes. 88 Unfortunately, very little is known regarding these conditions. However, the close association between AHSCT and immunosuppressive therapy suggests a potentially effective treatment for IHA 89 that needs further investigation in order to decrease the currently high rates of failure and death.…”